1,079
Views
33
CrossRef citations to date
0
Altmetric
Author's View

Cancer testis antigens

A new paradigm for cancer therapy

, , , , , , , & show all
Pages 1194-1196 | Received 07 May 2012, Accepted 08 May 2012, Published online: 01 Oct 2012

References

  • Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10 - 29; http://dx.doi.org/10.3322/caac.20138; PMID: 22237781
  • Suri A. Cancer testis antigens--their importance in immunotherapy and in the early detection of cancer. Expert Opin Biol Ther 2006; 6:379 - 89; http://dx.doi.org/10.1517/14712598.6.4.379; PMID: 16548764
  • Scudellari M. A ballsy search for cancer targets. Nat Med 2011; 17:916 - 8; http://dx.doi.org/10.1038/nm0811-916; PMID: 21818078
  • Jagadish N, Rana R, Selvi R, Mishra D, Garg M, Yadav S, et al. Characterization of a novel human sperm-associated antigen 9 (SPAG9) having structural homology with c-Jun N-terminal kinase-interacting protein. Biochem J 2005; 389:73 - 82; http://dx.doi.org/10.1042/BJ20041577; PMID: 15693750
  • Garg M, Kanojia D, Khosla A, Dudha N, Sati S, Chaurasiya D, Jagadish N, Seth A, Kumar R, Gupta S, Gupta A, Lohiya NK, Suri A. Sperm associated antigen 9 is associated with tumor growth, migration and invasion in renal cell carcinoma. Cancer Res 2008; 68:8240 - 48; PMID: 18922895; http://dx.doi.org/10.1158/0008-5472.CAN-08-1708
  • Kanojia D, Garg M, Gupta S, Gupta A, Suri A. Sperm associated antigen 9 (SPAG9), a novel biomarker for early detection of breast cancer. Cancer Epidemiol Biomarkers Prev 2009; 18:630 - 9; PMID: 19190149
  • Kanojia D, Garg M, Gupta S, Gupta A, Suri A. Sperm-associated antigen 9 is a novel biomarker for colorectal cancer and is involved in tumor growth and tumorigenicity. Am J Pathol 2011; 178:1009 - 20; http://dx.doi.org/10.1016/j.ajpath.2010.11.047; PMID: 21356354
  • Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A 2012; 109:5797 - 802; http://dx.doi.org/10.1073/pnas.1117208109; PMID: 22454499
  • Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res 2011; 17:7164 - 73; http://dx.doi.org/10.1158/1078-0432.CCR-11-0649; PMID: 22068656
  • Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:501 - 8; http://dx.doi.org/10.1016/S1470-2045(12)70006-2; PMID: 22326924